March 24, 2016 9:49am

 

… For Rheumatoid Arthritis and Other Rheumatic Conditions

 


 

The United States Patent and Trademark Office has granted a key patent covering the use of proprietary Mesenchymal Precursor Cells (MPCs) for the treatment or prevention of a broad range of rheumatic conditions, including rheumatoid arthritis.

 

The granted US Patent No. 9,265,796, entitled ‘Method of treatment or preventing rheumatic disease’, provides Mesoblast with commercial rights in the United States through July 4, 2032. Further patent term extension may occur along with regulatory exclusivity extensions.

 

The Bottom Line: The granted claims cover the use of cell populations enriched for MPCs, defined as STRO-1 positive multi-potential cells, which have been isolated from any tissue source and which may have been culture-expanded, for the treatment of various rheumatic diseases, including rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, sacroiliitis, enteric arthritis, and Reiter's syndrome.

Additionally, the granted claims cover the use of these cell populations to reduce levels of inflammatory cytokines TNF-alpha, interleukin-6, and interleukin-17, all established mediators of inflammatory arthritis in rheumatic diseases.

MPCs secrete potent immunomodulatory and anti-inflammatory factors and are thought to mediate their effects on inflammatory joint conditions by inhibiting multiple cytokine pathways implicated in joint inflammation of rheumatic diseases.

  • MESO has more than 661 patents or patent applications across at least 72 patent families which provide substantial competitive advantages for the commercial development of cell-based therapeutic products using mesenchymal lineage cells.

 

MESO closed at $9.50 and is UP +$0.52 or +5.48% at the open with 11.9 K shares traded - BUY